remogliflozin etabonate + metformin

Remogliflozin etabonate + metformin is a fixed-dose combination therapy, investigated for the treatment of type 2 diabetes mellitus. **Remogliflozin etabonate** is an orally active prodrug that is rapidly converted to remogliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion. **Metformin** is a biguanide antihyperglycemic agent that lowers hepatic glucose production and increases insulin sensitivity, and is considered first-line therapy in type 2 diabetes. The combination is designed to improve glycemic control utilizing complementary mechanisms of action, and combination studies have demonstrated safety, tolerability, and efficacy with no significant pharmacokinetic interactions observed[1][3][5].

Other names

GSK189075 + metforminremogliflozin etabonate + metformin